



Zydus – Recall of acyclovir injection

- On March 24, 2021, [Zydus announced](#) a voluntary, user-level recall of four lots of [acyclovir](#) 50 mg/mL injection after receiving several complaints of crystallization in vials.
 - Clinical Services, through the Drug Safety Notification program, did not identify any members that may have used the recalled medication, thus mailings will not be conducted.
- The recalled lots are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Acyclovir sodium injection, 50 mg/mL, 20 mL; 10x20 mL, single dose vial pack	68382-049-10 (carton); 68382-049-01 (vial)	L000155 (12/2021); L000156 (1/2022)
Acyclovir sodium injection 50 mg/mL, 10 mL; 10x10 mL, single dose vial pack	68382-048-10 (carton); 68382-048-01 (vial)	L000126 (12/2021); L000127 (12/2021)

- Acyclovir injection is indicated for the treatment of herpes simplex infections in immunocompromised patients, severe initial clinical episodes of herpes genitalis in immuno-competent patients, herpes simplex encephalitis, neonatal herpes simplex virus infection and varicella-zoster (shingles) infections in immunocompromised patients.
- Administration of crystalized acyclovir injection has a potential of life-threatening adverse consequences including injection site inflammation of a vein and local reactions, damage and/or obstruction of blood vessels, which could induce clots, particularly in the lungs, the passage of the particulate matter into the bloodstream may lead to clots resulting in stroke, heart attack, decreased liver or kidney function or death of tissues or cells.
- To date, Zydus has not received any reports of adverse events related to this product recall.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled acyclovir.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Zydus by phone at 1-877-993-8779 or by email at medicalaffairs@zydususa.com for more information about this recall.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.